News & Updates
Filter by Specialty:
FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?
A combination of trifluridine/tipiracil (FTD/TPI) and bevacizumab provided significant survival benefit when used as third-line treatment for refractory metastatic colorectal cancer (CRC) than FTD/TPI alone, findings from the phase III SUNLIGHT study suggest.
FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?
16 Feb 2023
Prophylactic aflibercept reduces vision-threatening complications without gains in visual acuity
Treatment with intravitreal aflibercept in patients with nonproliferative diabetic retinopathy but without centre-involved diabetic macular edema appears to slow disease progression and reduce the risk of developing vision-threatening complications but fall short of improving visual acuity, according to a study.
Prophylactic aflibercept reduces vision-threatening complications without gains in visual acuity
15 Feb 2023
Outpatient oritavancin bests inpatient SoC in acute uncomplicated cellulitis
Outpatient oritavancin therapy appears to be more effective than inpatient standard-of-care (SoC) in reducing 30-day hospital readmissions or admissions among individuals with acute uncomplicated cellulitis, a recent study has shown.
Outpatient oritavancin bests inpatient SoC in acute uncomplicated cellulitis
15 Feb 2023
Aspirin as good as heparin for thromboprophylaxis in patients with fractures
Thromboprophylaxis with aspirin in patients with extremity fractures appears to prevent death and lower the incidences of deep-vein thrombosis and pulmonary embolism without any significant differences as compared with thromboprophylaxis with low-molecular-weight heparin, according to a study.
